AI Solutions

Radiation Oncology

AI Powered Workflows for Radiation Oncology

Zero click AI workflows for high-precision radiotherapy. In clinical use across Europe and US with up to 90% time saving for dosimetrists, RTTs and radiation oncologists.

RT workflow solutions

ART-Plan™ is a web-browser based, scalable and modular AI automation platform for radiotherapy.  Current modules include:

Annotate™: AI-powered software that provides fully automatic delineation of 150+ CT and MRI-based organs at risk (OARs) and lymph nodes from Simulator-to-TPS within 2-3 minutes and with the same accuracy as clinical experts, utilizing latest consensus contouring guidelines.

MR-Box™: Generates MRI-based pseudo-CT (conventional MRIs and MR linacs) for MR-only and MR guided radiotherapy to avoid registration errors, cost saving and improved patient comfort. Compatible standard MRIs and with Annotate for auto-contouring of OARs & lymph nodes.

SmartFuse™: The first AI-powered software for high-precision rigid and elastic fusion, that includes the management of 4D-CT and a real-time deformation of contours for faster replanning.

AdaptBox™ *: Provides decision making support using customisable objective metrics for adaptive radiotherapy by utilizing AI to generate an enhanced and augmented pseudo-CT from CBCT with a CT-like FOV, expert like contours using AI auto-contouring as well as re-calculating and comparing dose metrics to the active treatment plan.

IT deployment: The ART-Plan AI automation platform is web-browser based and can be deployed via cloud or locally as per IT preference.

* Not yet available for sale.  Commercial launch est. for 2023. 

Afspil video
Implementing AI in RT – most common mistakes

We often see implementation of AI workflows being overcomplicated

About Therapanacea

TheraPanacea is a serial award-winning medical technology company founded in 2017 harnessing AI to develop cutting-edge software for more efficient and precise cancer care. Their radiotherapy AI automation platform ART-Plan™ has been CE-marked in 2019 (FDA clearance, etc. followed soon) and since then ART-Plan is already in use across Europe and US.